RORγ antagonists suppress NGF expression and inhibit its downstream signaling pathways, whereas exogenous NGF supplementation or overexpression of NGF notably reverses the inhibitory effects of RORγ antagonists on NSCLC cells.<h4>Conclusion</h4>Taken together, these results establish RORγ as a critical regulator of NSCLC and a promising therapeutic target for NSCLC treatment. The gene discussed is NGF; the disease is non-small cell lung carcinoma.